Thomas Eigentler

20.4k citations
266 papers · 9.3k · 2 hit papers · h-index 48

Impact in

  • Oncology top 0.2%
    • Cutaneous Melanoma Detection and Management
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
  • Immunology top 1%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

    • Cutaneous Melanoma Detection and Management 123
    • Cancer Immunotherapy and Biomarkers 44
    • CAR-T cell therapy research 42
    • Polyomavirus and related diseases 8
    • Melanoma and MAPK Pathways 55

Thomas Eigentler

254 papers receiving 9.2k citations

Thomas Eigentler's Hit Papers

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial 2020 · 453 citations
4530+4+8Years since publication100200300400

Peers

Thomas Eigentler
Comparison fields: 5 of 151
  • Oncology 5.5k
  • Immunology 2.1k
  • Dermatology 741
  • Molecular Biology 2.8k
  • Epidemiology 1.1k
Replace Alessandro Testori with:
Alessandro Testori Italy
Jane L. Messina United States
Svetomir N. Markovic United States
Alan Spatz France
John A. Thompson United States
Mark B. Faries United States
Carola Berking Germany
Hensin Tsao United States
Mohammed Kashani–Sabet United States
Mark R. Middleton United Kingdom
Thomas Eigentler relative to Alessandro Testori Italy Alessandro Testori's profile →
Citations per field
00.5×1.5×2.5×
Alessandro Testori · 1×
Citations per year

Countries citing papers authored by Thomas Eigentler

Since Specialization
Citations

This map shows the geographic impact of Thomas Eigentler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Eigentler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Eigentler more than expected).

Fields of papers citing papers by Thomas Eigentler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Eigentler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Eigentler. The network helps show where Thomas Eigentler may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Eigentler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Eigentler Line = papers co-authored together Thomas Eigentler links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 266 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2020453
2
Epidemiology of Skin Cancer
Hit paper breakdown →
2014452
3 2011431
4 2016311
5 2009306
6 2019253
7 2017241
8 2003235
9 2008207
10 2008190
11 2007168
12 2019162
13 2003144
14 2017142
15 2019137
16 2007133
17 2011125
18 2010120
19 2010116
20 2017112

About Thomas Eigentler

Thomas Eigentler is a scholar working on Oncology, Molecular Biology, Immunology, Epidemiology and Dermatology, having authored 266 papers that have together received 9.3k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (123 papers), Melanoma and MAPK Pathways (55 papers), Cancer Immunotherapy and Biomarkers (44 papers), CAR-T cell therapy research (42 papers), Immunotherapy and Immune Responses (39 papers), Nonmelanoma Skin Cancer Studies (30 papers), Cutaneous lymphoproliferative disorders research (16 papers) and Polyomavirus and related diseases (8 papers). The work is most often cited by research in Oncology (5.5k citations), Immunology (2.1k citations), Dermatology (741 citations), Molecular Biology (2.8k citations) and Epidemiology (1.1k citations). Thomas Eigentler has collaborated with scholars based in Germany, United States and Australia. Frequent co-authors include Claus Garbe, Ulrike Leiter, Benjamin Weide, Friedegund Meier, Ralf Gutzmer, Axel Hauschild, Peter Radny, Helmut Breuninger, Annette Pflugfelder and Andrea Forschner. Their work appears in journals such as Journal of Clinical Oncology, JDDG Journal der Deutschen Dermatologischen Gesellschaft, Annals of Oncology, European Journal of Cancer and Melanoma Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact